YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Is ALX Oncology Holdings Inc. (ALXO) one of those stocks right now? A quick glance at the company's year…
bioAffinity Technologies, Inc.'s BIAF investors have been experiencing some short-term losses. Shares of the San Antonio, TX-based biotechnology company have lost 77% in the past three months against the industry's 4.5% rise. It has also u…
Earnings Call Insights: ALX Oncology (ALXO) Q1 2026 MANAGEMENT VIEW * "Most notably, we are very excited to share with you the data set that was presented yesterday in Munich at ESMO Breast 2026 from the analysis of our trial evaluating ev…
ALX Oncology - Data from Phase 1b/2 trial presented at ESMO Breast Cancer 2026 further validate a biomarker-driven development strategy for evorpacept - - Findings are consistent with previous results from the randomized ASPEN-06 trial in…
ALX Oncology - Company Will Discuss Data and Report First Quarter 2026 Financial Results on May 8 - SOUTH SAN FRANCISCO, Calif., April 30, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. ("ALX Oncology"; Nasdaq: ALXO), a clinical-stage…
SOUTH SAN FRANCISCO, Calif., April 17, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. (“ALX Oncology,” Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend p…
bioAffinity Technologies, Inc. BIAF investors have been experiencing some short-term gains lately, despite the stock’s bumpy ride in recent months. Shares of the diagnostics company specializing in the development of non-invasive tests to…
Shares of Aldeyra Therapeutics ALDX plunged 70.7% on Tuesday after the company announced receiving a Complete Response Letter (CRL) from the FDA for a third time for the new drug application (NDA) seeking approval of reproxalap, an investi…
Shares of CytomX Therapeutics CTMX soared 44.2% on Monday after the company reported positive phase I expansion data for its EpCAM-targeting PROBODY ADC, varsetatug masetecan (Varseta-M), in late-line metastatic colorectal cancer (CRC) fro…
Shares of ImmunityBio IBRX rose more than 7% on Friday after the company announced that it completed two manufacturing engineering programs for its autologous memory cytokine-enhanced natural killer (M-ceNK) cell therapy platform. The comp…
Johnson & Johnson JNJ reported positive results from an early-stage study evaluating its investigational intravesical drug-releasing system with erdafitinib (Erda-iDRS) in patients with intermediate-risk and high-risk non–muscle-invasive b…
Allogene Therapeutics ALLO incurred a fourth-quarter 2025 loss of 17 cents per share, narrower than the Zacks Consensus Estimate of a loss of 25 cents. In the year-ago period, the company had reported a loss of 28 cents. As the company lac…
Ultragenyx Pharmaceutical RARE reported positive results from a late-stage study of its investigational AAV8 gene therapy, DTX301, for the treatment of ornithine transcarbamylase (OTC) deficiency. The candidate is designed to provide durab…
Shares of Relmada Therapeutics RLMD rallied 42% in a week after the company announced positive 12-month interim data from its ongoing mid-stage study evaluating NDV-01 in patients with high-risk non-muscle invasive bladder cancer (NMIBC).…
GSK plc GSK signed a license agreement with Italy-based Alfasigma. Per the terms of the agreement, Alfasigma has acquired exclusive global rights from GSK to develop and market linerixibat, an investigational therapy for treating cholestat…
Editas Medicine EDIT reported a loss of 6 cents per share in the fourth quarter of 2025, narrower than the Zacks Consensus Estimate of a loss of 27 cents. The company had incurred a loss of 55 cents per share in the year-ago quarter. The c…
Roche RHHBY announced results from a late-stage study evaluating its investigational candidate, giredestrant, in combination with palbociclib for patients with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2…
UBS initiated coverage of ALX Oncology (ALXO) with a Buy rating and $6 price target The company has a potential blockbuster program with a CD47 combo currently in Phase II for metastatic breast cancer, the analyst tells investors in a rese…
Shares of Larimar Therapeutics LRMR rose 55% in the past month after the company announced key regulatory updates related to nomlabofusp, its lead pipeline asset. Larimar outlined upcoming milestones related to the drug. LRMR Secures Break…
Shares of uniQure N.V. QURE plunged 31.8% in a week, primarily after the company announced a disappointing regulatory update for its investigational gene therapy, AMT-130, for the treatment of Huntington’s disease, earlier in March. uniQur…
Mirum Pharmaceuticals MIRM announced that it has completed enrollment in the phase III AZURE-1 study, evaluating its pipeline candidate, brelovitug, for the treatment of chronic hepatitis delta virus (HDV). Simultaneously, the company comp…
Can-Fite BioPharma CANF shares soared 20.4% on Wednesday after the company reported positive top-line results from a mid-stage study of its investigational candidate, namodenoson, in patients with advanced pancreatic ductal adenocarcinoma…
Acadia Pharmaceuticals ACAD announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has formally adopted a negative opinion recommending against the approval of trofinetide for the tr…
Acadia Pharmaceuticals ACAD announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has formally adopted a negative opinion recommending against the approval of trofinetide for the tr…
Earnings Call Insights: ALX Oncology Holdings Inc. (ALXO) Q4 2025 MANAGEMENT VIEW * Jason Lettmann, CEO, introduced the appointment of Dr. Barbara Klencke as the permanent Chief Medical Officer, following her interim leadership since Septe…
- Clinical development for both the investigational CD47-inhibitor evorpacept and the novel EGFR-targeted antibody-drug conjugate ALX2004 remains on track following strong 2025 execution; company anticipates multiple meaningful data sets a…
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Is Teva Pharmaceutical Industries Ltd. (TEVA) one of those stocks right now? A quick glance at the comp…
As February begins, major U.S. stock indexes have shown strong gains, with the Dow Jones Industrial Average adding 515 points and the S&P 500 nearing a record high. In this context of market optimism, investors often seek out opportunities…
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Is ALX Oncology Holdings Inc. (ALXO) one of those stocks right now? Let's take a closer look at the stock's year-to-date pe…
[Health Care Medical Stock Market Industry Sector Wall Street Buildings 3d Illustration] iQoncept/iStock via Getty Images As earnings season ramps up and geopolitical tensions keep affecting the markets, below is a list of the top 10 healt…
ALX Oncology - Exploratory analysis from Phase 1b/2 breast cancer trial reinforces CD47 as a predictive biomarker for response, as previously observed in the ASPEN-06 trial in HER2-positive gastric cancer – - Full data set submitted for pr…
- Exploratory analysis from Phase 1b/2 breast cancer trial reinforces CD47 as a predictive biomarker for response, as previously observed in the ASPEN-06 trial in HER2-positive gastric cancer – - Full data set submitted for presentation at…
SOUTH SAN FRANCISCO, Calif., Jan. 08, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. ("ALX Oncology"; Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend pa…
ALX Oncology SOUTH SAN FRANCISCO, Calif., Jan. 08, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. ("ALX Oncology"; Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer…
(RTTNews) - Several biotechnology and healthcare companies posted notable gains in after-hours trading on Wednesday, driven by clinical updates, financial results, and upcoming industry presentations. ALX Oncology Holdings Inc. (ALXO) surg…
- Combination of evorpacept plus rituximab and lenalidomide (R2) generated complete responses (CR) in 92% of patients with untreated indolent non-Hodgkin lymphoma (iNHL) comparing favorably to an approximate 50% historical CR rate for R2 a…